Table 2.
Outcome according to antiviral treatment
| No antiviral | Lopinavir ritonavir | Hydroxychloroquine | Othera | Pb value | |
|---|---|---|---|---|---|
| N = 85 | N = 57 | N = 220 | N = 53 | ||
| Ventilatory mode at day 14, n (%) | |||||
| Death | 0.32 | ||||
| Controlled mode or under VV- | 15 (18) | 12 (21) | 58 (27) | 9 (17) | |
| ECMO | 27 (32) | 20 (35) | 72 (33) | 22 (42) | |
| Pressure support | 16 (19) | 12 (21) | 45 (21) | 14 (26) | |
| Extubated | 27 (32) | 13 (23) | 44 (20) | 8 (15) | |
| Alive at day 28, n (%) | 62 (73) | 35 (61) | 140 (64) | 38 (72) | 0.30 |
| VFD at day 28, median [IQR] | 5 [0–15] | 0 [0–11] | 0 [0–12] | 0 [0–9] | 0.03 |
| N = 80/49/197/7/43 | |||||
| Acute kidney injury, n (%) | |||||
| No | 38 (45) | 17 (30) | 106 (48) | 22 (42) | 0.002 |
| Yes without RRT | 33 (39) | 18 (32) | 72 (33) | 26 (49) | |
| Yes with RRT | 14 (17) | 22 (39) | 41 (19) | 5 (9) | |
| Peak of creatinine, median [IQR] | 115 [84–209] | 198 [95–432] | 122 [80–316] | 145 [88–245] | 0.05 |
| N = 84/52/218/53 | |||||
| Acute cardiac injury, n (%) | 8 (9) | 6 (10) | 37 (17) | 4 (8) | 0.14 |
| Pulmonary embolism, n (%) | 11 (13) | 6 (11) | 32 (15) | 10 (19) | 0.78 |
| Deep venous thrombosis, n (%) | 7 (8) | 8 (14) | 20 (9) | 4 (8) | 0.62 |
| ICU survival, n (%) | 56 (67) | 27 (51) | 123 (57) | 34 (64) | 0.22 |
| N = 406 | |||||
a Other including HCQ + L/R N = 32; HCQ + REM N = 10; REM N = 11
b P value was calculated using Chi-2, ANOVA, Kruskal–Wallis as appropriate
RRT renal replacement therapy, VFD ventilator-free days, VV-ECMO veno-venous extracorporeal membrane oxygenation